Stay updated with breaking news from First Trade Under. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ABVC BioPharma said that the licensing agreement includes the ophthalmology pipeline, including the medical device Vitargus licensed products' and clinical trial, registration, manufacturing, supply, and distribution rights.
Evercore ISI Group analyst Michael Montani maintained Carvana with an In-Line rating and raised the price target on the stock from $68 to $75 Tuesday. Carvana received two significant analyst upgrades earlier in March, one from Jefferies analyst John Colantuoni who upgraded Carvana from an Underperform to a Hold rating and raised the price target from $30 to $85. RBC Capital analyst Brad Erickson also upgraded the stock from Underperform to Sector Perform and raised its price target from $45 to $90 on March 8.
The company announced the release of MicroStrategy Auto on Tuesday. MicroStrategy describes Auto as a customizable AI bot that offers a faster, simpler way to deliver business intelligence to anyone in an organization and the latest enhancement to MicroStrategy AI, released in October 2023, a solution for rapidly building AI applications on trusted data.
Rumble shares are trading higher Tuesday, possibly in sympathy with Trump Media & Technology Group Corp. after the company debuted on the Nasdaq Tuesday. Trump Media & Technology Group made its debut on the Nasdaq Tuesday and is trading up 35% at the time of publication.
Shockwave Medical shares are trading higher Tuesday following a report suggesting Johnson & Johnson is in talks to acquire the company. According to a report from the Wall Street Journal, people familiar with the matter say that a deal to acquire the company could be completed in the coming weeks. Shockwave Medical shares have gained more than 65% year-to-date, and the company has a market value of nearly $11 billion.